Development of novel anti-cancer immunotherapy against mesothelioma comprising of oncolytic adenovirus vectors armed with ICOS and CD40 ligands in combination with checkpoint inhibitors anti-PD-1 and anti-CTLA-4.
The proposed research project seeks to develop a new treatment regime in mesothelioma therapy. Therefore, to continue a new research front within the field of immuno-oncology utilizing oncolytic adenoviruses in Poland. Despite major advances in cancer treatments by surgery, chemotherapy, radiotherapy, immunotherapy and their combination, the outcome remains partially ineffective against numerous cancer types like mesothelioma. Furthermore, due to resistance factors and the subsequent loss of response, which may occur rapidly during the conventional treatment regimes, new anti-cancer agents, presenting new mechanisms of action and lacking cross-resistance to commonly used therapies, are in high demand. Malignant mesothelioma (MM) is a treatment-resistant cancer to standard therapies with no effective curative options for advanced cancer patients.
Project is funded by Polish National Science Centre (NCN)
Warsaw University of Technology
Narodowy Instytut Zdrowia Publicznego PZH
Total: 1.930.370,00 PLN (WUT: 249.210,00 PLN)